49P Analysis of HER2-low carcinomas and PAM50 signature in an early-stage breast cancer cohortRodrigo Sánchez-Bayona, Eva Ciruelos, Pablo Tolosa et al.|Annals of Oncology|2022Cited by 1
38P Impact of 1-year COVID-19 pandemic in patients with ovarian carcinoma treated with chemotherapy based on a global data networkL.M. Manso Sànchez, L. Paz-Ares, Gema Hernández et al.|Annals of Oncology|2022Cited by 0
248P Real-world relapse-free survival in HR+/HER2- breast cancer with PAM50 intermediate-risk groupSantiago Terán, Rodrigo Sánchez-Bayona, M. Quevedo et al.|ESMO Open|2025Cited by 0
146P Malignant bowel obstruction (MBO) symptom monitoring through artificial intelligence (AI) based automated calls in gynecologic cancersA. Madariaga Urrutia, Isabel Tuñon, S. Sanchez-Castro et al.|ESMO Open|2025Cited by 0
2878P Impact of skeletal muscle mass on trastuzumab deruxtecan (t-dxd) toxicity in solid tumorsW.G. Parra Paladines, A. Madariaga Urrutia, Rodrigo Sánchez-Bayona et al.|Annals of Oncology|2025Cited by 0